lenograstim

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 447995983

| IUPAC_name =

| image =

| tradename = Euprotin, Granocyte, Lenobio, Neutrogin

| Drugs.com = {{drugs.com|international|lenograstim}}

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 135968-09-1

| ATC_prefix = L03

| ATC_suffix = AA10

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 6WS4C399GB

| chemical_formula =

| molecular_weight =

}}

Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an immunostimulator.{{cite journal | title = USAN Council. List No. 340. New names. Lenograstim | journal = Clin. Pharmacol. Ther. | volume = 52 | issue = 1 | pages = 112–113 |date=July 1992 | pmid = 1284891 | doi = 10.1038/clpt.1992.117 | s2cid = 221603616 }}{{cite journal |vauthors=Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T | title = Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study | journal = Blood | volume = 106 | issue = 1 | pages = 27–34 |date=July 2005 | pmid = 15761020 | pmc = 1895135 | doi = 10.1182/blood-2004-09-3728 }} It is developed by Chugai Pharmaceuticals under the brand name Granocyte.